Barriers to Accessing HCV Therapies in the US

Recent study indicates that newly available, interferon-free HCV therapies will significantly increase access to care for HCV infected individuals in the US, as unlike standard interferon-based therapies, interferon-free therapies are associated with minimal contraindications. However, a large proportion of US individuals with chronic hepatitis C infection are uninsured or under-insured, and this lack of adequate insurance coverage ...

Read More


Free HCV Peer-Reviewed PDF Bonanza!!!

Posted on May 25, 2015

From now until the end of the month only! Free HCV Peer-Reviewed PDF Bonanza!!! To satisfy your educational needs, Elsevier Multimedia Publishing has made available approximately 40 new, peer-reviewed, full text articles for free! Please see below for a list of these articles, which can readily be accessed in our American Journal of Medicine Hepatitis C Resource Center (hepcresource.amjmed.com). Note that ALL currently available, free, ...

Read More


EASL 2015 Hepatitis Research: Dr A. Ploss

For more information on the selected EASL 2015 Hepatitis abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Abstract G09 Targeting a Host-Cell Entry Factor Barricades Antiviral Resistant HCV Variants From On-Therapy Breakthrough In Human-Liver Mice Vercauteren K et al. The International Liver Congress™ 2015, 50th annual meeting of the European ...

Read More


Pooled safety data: ledipasvir/sofosbuvir: HCV-1

Posted on May 17, 2015

Pooled analysis of safety data from the three multicenter, randomized, open-label ION Phase 3 clinical trials shows that the addition of ribavirin to ledipasvir/sofosbuvir HCV-1 treatment regimens increased toxicity without providing additional efficacy. Eliminating ribavirin from HCV therapy will likely increase patient adherence to treatment due to an improved quality of life resulting from fewer adverse events, less laboratory monitoring, the ...

Read More


Largest DAA study to date in HCV genotype 4

Largest study to date shows that the two direct-acting antiviral drug-only regimen (ombitasvir plus paritaprevir) is effective and well tolerated in both treatment-naive and treatment-experienced patients with HCV genotype 4 infection without cirrhosis. Note that patients also received low-dose ritonavir to increase paritaprevir peak and trough concentrations and overall drug exposure. HCV genotype 4 is a heterogeneous genotype with multiple ...

Read More


Special Interview on HCV: Dr. S. Wiktor of WHO

Thank you for agreeing to participate in this special interview on HCV. What do you see as the biggest global challenges in the diagnosis, screening, and treatment of hepatitis C? Dr. Wiktor: The landscape is changing very quickly and it is being driven by remarkable progress in the development of direct-acting antiviral therapies for hepatitis C. We hear excitement at conferences like EASL and also from the journals, but this excitement has ...

Read More


New list: free peer-reviewed HCV articles: May 8

Posted on May 8, 2015

See below for a new list of free peer-reviewed HCV articles, available free for a limited time, only in our American Journal of Medicine Hepatitis C Resource Center (hepcresource.amjmed.com). New peer-reviewed, full-text articles in the section of the Resource Center focused toward Hepatologists, Gastroenterologists & Infectious Disease Specialists. Internal PubMed links provided for you to review the abstracts only, please visit ...

Read More


Newly Updated EASL 2015 HCV Guidelines

Posted on May 5, 2015

EASL 2015 HCV Guideline Recommendations: Summary Document and Full Report are Now Available for Download in Our American Journal of Medicine Hepatitis C Resource Center The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment guidelines at the 50th International Liver Congress, which took place last month in Vienna, Austria. Liz Highleyman, in collaboration with hivandhepatitis.com, has written an ...

Read More


Real-world evaluation of eligibility for HCV therapy

In clinical practices in Italy, between January 2009 and February 2010, only 61% of patients with chronic hepatitis C were considered eligible for peginterferon/ribavirin. Reasons treatment was not indicated included patient’s age or mild disease stage. Italian Hepatologists may consider an IFN-based antiviral treatment not cost-effective in older patients with mild HCV disease. Italy has the highest prevalence rates of hepatitis C ...

Read More


DAA HCV Regimen effective in pts with cirrhosis

Interferon free, direct acting antiviral HCV regimen ledipasvir-sofosbuvir with and without ribavirin is effective and well tolerated in adult patients with HCV genotype 1 and cirrhosis who have failed previous HCV therapy Chronically infected patients with cirrhosis, especially those who have failed previous hepatitis C therapy, achieve consistently lower rates of SVR than those without cirrhosis, in both clinical trials and real-world ...

Read More